Who has been buying L&C Bio stock?

6 distinct insiders have filed 6 disclosed insider purchases in L&C Bio (290650), most recently on 2026-04-23. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.

How many insider filings does L&C Bio have?

L&C Bio has 6 buy-side and 7 sell-side disclosures on record, covering ₩7.4B ($5.1M) in total reported value, spanning 2020-12-03 to 2026-04-23.

Where does StockDrifts get L&C Bio insider data?

From DART D001/D002 insider disclosures — the official filing system run by the Financial Supervisory Service (Korea). StockDrifts parses each disclosure and matches it to daily price history; the original filings remain available directly from DART.

Do insider buys in Korean stocks predict returns?

Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean DART filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

L&C Bio 290650

Company

엘앤씨바이오L&C Bio

Insiders

Buys

Total Value

₩7.4B ($5.1M)

Avg Return

-21.57%

Last Filing

2026-04-23

L&C Bio (290650) has 6 disclosed insider purchases and 7 disclosed disposals on record, filed by 6 distinct insiders. Together those filings cover ₩7.4B ($5.1M) in reported transaction value. The earliest filing StockDrifts holds for L&C Bio is dated 2020-12-03; the most recent is 2026-04-23. All of it is parsed from DART D001/D002 insider disclosures, the official disclosure system operated by the Financial Supervisory Service (Korea). Across these filings the average return since disclosure is -21.57%, measured from each filing date to the latest available close.

Price & insider activity (12 months)

Recent insider trades

Date	Type	Source	Insider	Position	Shares	Price at filing	Return	Value
2026-08-12	SELL	Market Sell	나우아이비19호펀드 Now Ivy Fund 19	-	-58.1K	₩56,800	+3.7%	₩3.3B ($2.3M)
2026-08-11	SELL	Market Sell	나우아이비19호펀드 Now Ivy Fund 19	-	-34.4K	₩63,500	+13.9%	₩2.2B ($1.5M)
2026-08-10	SELL	Market Sell	나우아이비19호펀드 Now Ivy Fund 19	-	-158.3K	₩64,600	+15.3%	₩10.2B ($7.1M)
2026-08-07	SELL	Market Sell	나우아이비19호펀드 Now Ivy Fund 19	-	-37.6K	₩62,000	+11.8%	₩2.3B ($1.6M)
2026-08-06	SELL	Market Sell	나우아이비19호펀드 Now Ivy Fund 19	-	-102.9K	₩63,800	+14.3%	₩6.6B ($4.6M)
2026-08-05	SELL	Market Sell	나우아이비19호펀드 Now Ivy Fund 19	-	-9.5K	₩57,800	+5.4%	₩547M ($380K)
2026-04-23	BUY	전환사채의권리행사	나우아이비19호펀드 Now Ivy Fund 19	-	2.1M	₩70,000	+23.1%	₩148.6B ($103.2M)
2026-04-23	BUY	신규등록	나우아이비19호펀드 Now Ivy Fund 19	-	493.8K	₩70,000	+23.1%	₩34.6B ($24.0M)
2026-04-23	BUY	신규등록	나우아이비19호펀드 Now Ivy Fund 19	-	707.5K	₩70,000	+23.1%	₩49.5B ($34.4M)
2026-02-23	SELL	Market Sell	한방희 Banghee Han	vice president	-10.0K	-	-	-
2026-02-20	SELL	Market Sell	이현승 Hyunseung Lee	moving	-350	-	-	-
2026-02-11	BUY	주식매수선택권	신성훈 Seonghun Shin	Managing Director	5.0K	₩93,400	+4.8%	₩467M ($324K)
2026-02-02	BUY	신규선임	이현승 Hyunseung Lee	moving	350	₩87,800	+11.5%	₩31M ($21K)
2026-01-30	SELL	Market Sell	한방희 Banghee Han	vice president	-20.0K	₩92,200	-6.2%	₩1.8B ($1.3M)
2026-01-14	BUY	Market Buy	손석우 Seokwoo Son	Managing Director	869	₩54,800	+33.9%	₩48M ($33K)
2026-01-05	BUY	Market Buy	손석우 Seokwoo Son	Managing Director	327	₩62,100	+18.2%	₩20M ($14K)
2026-01-02	BUY	Market Buy	손석우 Seokwoo Son	Managing Director	484	₩62,400	+17.6%	₩30M ($21K)
2025-12-24	SELL	Market Sell	임수성 Lim Su-seong	Managing Director	-16.1K	₩64,500	-51.8%	₩1.0B ($719K)
2025-12-23	SELL	Market Sell	임수성 Lim Su-seong	Managing Director	-13.9K	₩63,500	-54.2%	₩886M ($615K)
2025-12-18	BUY	주식매수청구권 행사	임수성 Lim Su-seong	Managing Director	30.0K	₩69,400	+41.1%	₩2.1B ($1.4M)
2025-12-18	BUY	주식매수청구권 행사	한방희 Banghee Han	vice president	40.0K	₩69,400	+41.1%	₩2.8B ($1.9M)
2025-11-17	BUY	Market Buy	손석우 Seokwoo Son	Managing Director	585	-	-	-
2025-11-17	BUY	Market Buy	손석우 Seokwoo Son	Managing Director	395	-	-	-
2025-09-23	SELL	Market Sell	김기민 Kim Ki-min	Managing Director	-28.8K	₩57,500	-70.3%	₩1.7B ($1.1M)
2025-09-18	SELL	Market Sell	이광인 Lee Kwang-in	Managing Director	-30.0K	₩61,200	-60.0%	₩1.8B ($1.3M)
2025-08-29	BUY	Market Buy	손석우 Seokwoo Son	Managing Director	1.0K	-	-	-
2025-06-29	SELL	전환권등소멸	이환철 Lee Hwan-cheol	CEO	-314.3K	₩27,750	-252.8%	₩8.7B ($6.1M)
2025-05-26	BUY	기타	이환철 Lee Hwan-cheol	CEO	187.0K	₩32,400	+202.2%	₩6.1B ($4.2M)
2025-05-26	SELL	기타	이환철 Lee Hwan-cheol	CEO	-187.0K	₩32,400	-202.2%	₩6.1B ($4.2M)
2025-05-26	SELL	기타	이환철 Lee Hwan-cheol	CEO	-187.0K	₩32,400	-202.2%	₩6.1B ($4.2M)
2024-09-29	BUY	행사가액조정	이환철 Lee Hwan-cheol	CEO	6.4K	₩20,550	+376.4%	₩132M ($91K)
2024-06-29	SELL	행사가액조정	이환철 Lee Hwan-cheol	CEO	-6.4K	₩24,900	-293.2%	₩160M ($111K)
2024-03-29	BUY	행사가액조정	이환철 Lee Hwan-cheol	CEO	93.8K	₩23,300	+320.2%	₩2.2B ($1.5M)
2020-12-03	BUY	신규선임	신성훈 Seonghun Shin	Managing Director	10.8K	₩35,400	+176.6%	₩382M ($266K)

Frequently asked questions

Who has been buying L&C Bio stock?: 6 distinct insiders have filed 6 disclosed insider purchases in L&C Bio (290650), most recently on 2026-04-23. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does L&C Bio have?: L&C Bio has 6 buy-side and 7 sell-side disclosures on record, covering ₩7.4B ($5.1M) in total reported value, spanning 2020-12-03 to 2026-04-23.
Where does StockDrifts get L&C Bio insider data?: From DART D001/D002 insider disclosures — the official filing system run by the Financial Supervisory Service (Korea). StockDrifts parses each disclosure and matches it to daily price history; the original filings remain available directly from DART.
Do insider buys in Korean stocks predict returns?: Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean DART filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

Source filings

Every trade listed above is disclosed in DART D001/D002 insider disclosures, filed with the Financial Supervisory Service (Korea). View the original DART filings for L&C Bio. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.